Eribulin Mesylate
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Malignant Neoplasm in the Adult Brain
Conditions
Metastatic Malignant Neoplasm in the Adult Brain, Primary Brain Tumor
Trial Timeline
May 19, 2015 → Mar 15, 2024
NCT ID
NCT02338037About Eribulin Mesylate
Eribulin Mesylate is a phase 1 stage product being developed by Eisai for Metastatic Malignant Neoplasm in the Adult Brain. The current trial status is completed. This product is registered under clinical trial identifier NCT02338037. Target conditions include Metastatic Malignant Neoplasm in the Adult Brain, Primary Brain Tumor.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03441360 | Phase 2 | Completed |
| NCT03583944 | Approved | Completed |
| NCT03361436 | Phase 1 | Active |
| NCT03437083 | Pre-clinical | Completed |
| NCT03058406 | Pre-clinical | Completed |
| NCT02481050 | Phase 2 | Completed |
| NCT02338037 | Phase 1 | Completed |
| NCT02171260 | Phase 1 | Completed |
| NCT03245112 | Pre-clinical | UNKNOWN |
| NCT01961544 | Approved | Completed |
| NCT01458249 | Phase 2 | Completed |
| NCT01463891 | Pre-clinical | Completed |
| NCT01328249 | Phase 2 | Completed |
| NCT01240421 | Pre-clinical | Completed |
| NCT01268150 | Phase 2 | Completed |
| NCT01269346 | Phase 2 | Completed |
| NCT01142661 | Pre-clinical | Completed |
| NCT01106248 | Phase 1 | Completed |
| NCT00965523 | Phase 2 | Completed |
Competing Products
20 competing products in Metastatic Malignant Neoplasm in the Adult Brain